APGE
Apogee Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +12 | 31.81M | $4.18B | +21 | −9 |
| Q1 2026 | 96 | +7 | 41.18M | $3.45B | +13 | −6 |
| Q4 2025 | 88 | 0 | 38.24M | $2.89B | — | — |
| Q3 2025 | 17 | -2 | 25.40M | $1.01B | — | −2 |
| Q2 2025 | 16 | +1 | 22.08M | $959.13M | +1 | — |
| Q1 2025 | 12 | -1 | 10.37M | $387.41M | — | −1 |
| Q4 2024 | 13 | +4 | 9.16M | $415.03M | +4 | — |
| Q3 2024 | 8 | -5 | 7.45M | $437.40M | — | −5 |
| Q2 2024 | 13 | — | 6.20M | $244.16M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.55M | — | $139.57M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 768.22K | — | $30.23M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 768.22K | — | $30.23M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 740.86K | — | $29.16M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 740.86K | — | $29.16M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 302.22K | — | $11.89M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 269.23K | — | $10.59M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 156.20K | — | $6.15M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 116.32K | — | $4.58M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 97.06K | — | $3.82M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 81.95K | — | $3.22M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Marshall Wace ✦ | 81.95K | — | $3.22M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 52.03K | — | $2.05M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 50.00K | — | $1.97M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Norges Bank ✦ (passive) | 12.12K | — | $476,961 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 11.54K | — | $453,902 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 11.54K | — | $453,902 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 77.95M shares, $5.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
9.8% of class · View original SEC filing ↗